Bayer's Q2 Numbers Look Stable-But €33.6B of Debt Make This a Hold, Not a Buy

Bayer's Q2 looked stable at the top, but the balance sheet still dominates

Bayer's second-quarter report was steady in the places investors like to see. Group sales rose 2.2 percent to €10.872 billion, and EBITDA before special items increased 1.9 percent to €2.144 billion. Management also confirmed the currency-adjusted Group outlook for 2026 and said the business remains operationally on track.

Cash and debt still tell the fuller story

The weaker signals sat underneath the headline numbers. Free cash flow fell to minus €371 million, net financial debt stood at €33.647 billion, and core EPS dropped 16.7 percent to €0.95. That combination does not confirm a full turnaround; it suggests the story still needs more proof.

Bulls can point to continued sales and EBITDA growth, plus management's view that litigation containment is in a stronger place. Bears, though, still have the stronger argument: a company with more than €33 billion of debt needs better cash generation before a rerating feels fully justified.

For that reason, Bayer still looks more like a hold than a buy until cash flow improves enough to back up the turnaround narrative.

Crop Science carried Q2, but the recovery still looks uneven

Crop Science did the heavy lifting

Bayer's quarter worked because Crop Science delivered. The segment reported higher sales and substantial earnings growth. That is meaningful because it is the business most exposed to normalization after a tight corn-area cycle.

That strength gives bulls a real operating argument. At least part of the base is improving, not just the market story around it.

Pharmaceuticals and Consumer Health cooled the headline growth

The problem is mix. Bayer did not post a fully balanced recovery.

That matters more than the headline sales and EBITDA gains. If two of three divisions are neutral or negative on earnings, the quarter looks more like a one-engine performance than a company-wide turnaround. That raises the question of how durable the growth really is.

"On track" is directional, not final proof

Management said Bayer is operationally on track for the year, and the half-year materials also pointed to progress in Pharmaceuticals pipeline rejuvenation, Crop Science's Five-Year Framework, and the company's position on the proposed class settlement agreement.

That supports management's message. It does not settle the bear case.

"On target" describes direction and progress; it does not mean the debt burden is resolved, litigation is behind the company, or cash flow has stabilized.

What would change the view from here?

The key question is whether Crop Science's quarter was the start of a structural recovery or another phase-driven bounce.

Watch for: - whether Crop Science can repeat that strength over multiple quarters - whether Pharmaceuticals stops weighing on earnings while sales remain only at the prior-year level - whether the proposed class settlement agreement brings real cash and timing relief - whether free cash flow moves back toward break-even or positive territory